Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S. R., Deo R., et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–e603. doi: 10.1161/CIR.0000000000000485..
DOI: 10.1161/CIR.0000000000000485
Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. ehz425. doi: 10.1093/eurheartj/ehz425..
DOI: 10.1093/eurheartj/ehz425
Roffi M., Patrono C., Collet J.P., Mueller C., Valgimigli M., Andreotti F., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. doi: 10.1093/eurheartj/ehv320..
DOI: 10.1093/eurheartj/ehv320
Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393..
DOI: 10.1093/eurheartj/ehx393
Bonaca M.P., Bhatt D.L., Cohen M., Steg P.G., Storey R.F., Jensen E.C., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800; doi: 10.1056/NEJMoa1500857..
DOI: 10.1056/NEJMoa1500857
Neumann F.-J., Sousa-Uva M., Ahliston A., Alfonso F., Banning A. P., Benedetto U., et al. 2018 ESC/EACT Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–
doi: 10.1093/eurheartj/ehy394..
DOI: 10.1093/eurheartj/ehy394
Valgimigli M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–260. doi: 10.1093/eurheartj/ehx419..
DOI: 10.1093/eurheartj/ehx419
Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717; doi: 10.1056/NEJMoa060989..
DOI: 10.1056/NEJMoa060989
Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982–1988. doi: 10.1016/j.jacc.2007.03.025..
DOI: 10.1016/j.jacc.2007.03.025
Morrow D.A., Braunwald E., Bonaca M.P., Ameriso S.F., Dalby A.J., Fish M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–1413. doi: 10.1056/NEJMoa1200933..
DOI: 10.1056/NEJMoa1200933
Mega J.L., Braunwald E., Wiviott S.D., Bassand J.-P., Bhatt D.L., Bode C., et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366:9–19. doi: 10.1056/NEJMoa1112277..
DOI: 10.1056/NEJMoa1112277
Eikelboom J.W., Connolly S.J., Bosch J., Dagenais G.R., Hart R.G., Shestakovska O., et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319–1330. doi: 10.1056/NEJMoa1709118..
DOI: 10.1056/NEJMoa1709118
Connolly S.J., Eikelboom J.W., Bosch J., Dagenais G., Dyal L., Lanas F., et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205–218. doi: 10.1016/S0140-6736(17)32458-3..
DOI: 10.1016/S0140-6736(17)32458-3
Bonaca M.P., Bhatt D.L., Steg G., Storey R.F., Cohen M., Im K., et al. Ischaemic risk and efficacy of ticagrelor in relation to time prior from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37(14):1133–1142. doi: 10.1093/eurheartj/.
DOI: 10.1093/eurheartj/